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Abstract: Uptake of intermittent preventive therapy in pregnancy (IPTp) with sulfadoxine-pyrimethamine
(IPTp-SP) is a clinically-proven method to prevent the adverse outcomes of malaria in pregnancy (MiP)
for the mother, her foetus, and the neonates. The majority of countries in sub-Saharan Africa have
introduced IPTp policies for pregnant women during the past decade. Nonetheless, progress towards
improving IPTp coverage remains dismal, with widespread regional and socioeconomic disparities
in the utilisation of this highly cost-effective service. In the present study, our main objective was to
measure the prevalence of IPTp uptake in selected malaria-endemic countries in sub-Saharan Africa,
and to investigate the patterns of IPTp uptake among different educational and wealth categories
adjusted for relevant sociodemographic factors. For this study, cross-sectional data on 18,603 women
aged between 15 and 49 years were collected from the Malaria Indicator Surveys (MIS) conducted in
Burkina Faso, Ghana, Mali, Malawi, Kenya, Nigeria, Sierra Leone, and Uganda. The outcome variable
was taking three doses of IPTp-SP in the last pregnancy, defined as adequate by the WHO. According
to the analysis, the overall prevalence of taking three doses of IPTp-SP in the latest pregnancy was
29.5% (95% CI = 28.2–30.5), with the prevalence being highest for Ghana (60%, 95% CI = 57.1–62.8),
followed by Kenya (37%, 95% CI = 35.3–39.2) and Sierra Leone (31%, 95% CI = 29.2–33.4). Women
from non-poor households (richer—20.7%, middle—21.2%, richest—18.1%) had a slightly higher
proportion of taking three doses of IPTp-SP compared with those from poorest (19.0%) and poorer
(21.1%) households. Regression analysis revealed an inverse association between uptake of IPTp-SP
and educational level. With regard to wealth status, compared with women living in the richest
households, those in the poorest, poorer, middle, and richer households had significantly higher
odds of not taking at least three doses of IPTp-SP during their last pregnancy. The present study
concludes that the prevalence of IPTp-SP is still alarmingly low and is significantly associated with
individual education and household wealth gradient. Apart from the key finding of socioeconomic
disparities within countries, were the between-country variations that should be regarded as a marker
of inadequate policy and healthcare system performance in the respective countries. More in-depth
and longitudinal studies are required to understand the barriers to, and preferences of, using IPTp-SP
among women from different socioeconomic backgrounds.
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1. Introduction
Malaria is historically recognised as a significant public health concern for healthcare systems in
sub-Saharan Africa (SSA), and to date remains a major contributor to maternal and infant morbidity
and mortality in the continent [1–3]. Led by strong political commitments and programmatic efforts
by national and international agencies, most countries in SSA have achieved noteworthy progress
in increasing the coverage of insecticide-treated nets (ITNs) and antimalarial intermittent preventive
therapy in pregnancy (IPTp) that has brought about a subsequent reduction in the prevalence of
malaria in the population [4–6]. There is a growing body of evidence that in the endemic regions
malaria in pregnancy (MiP) remains a prominent preventable cause of maternal and infant morbidity
and mortality [7], accounting for about 75,000–200,000 infant deaths in the region [8,9]. Despite this
evidence and the ongoing malaria elimination efforts, the rate of utilisation of preventive measures,
especially IPTp, is still unsatisfactory and is far from being universal [4].
Commonly known as a disease of poverty, there are also certain demographic patterns in the
distribution of the epidemic that cause pregnant women and infants to bear the greatest risk of the most
severe clinical symptoms of malaria [10]. MiP is associated with a range of complications for mothers,
fetuses, and neonates including maternal hypoglycaemia, intrauterine growth retardation, placental
malaria (PM), fetal hypotrophy, miscarriage, preterm delivery, and low birth weight, which explains
the contribution of malaria to higher maternal and neonatal mortality rates [11–13]. The majority of the
complications of MiP are caused by Plasmodium falciparum, although the severity of the symptoms and
complications can vary across regions and the degree of acquired immunity among the individuals.
Mechanisms responsible for heightened susceptibility to malaria during gestational period have
been explained by clinical studies. In P. falciparum infection, the infected erythrocytes are reported to
sequester in the placenta and produce a unique type of surface antigen (unique variant surface antigens
(VSA) [14] that is more likely to go unrecognized due to a lower immune system response during
pregnancy [15]. In the case of primigravid woman, the risk of severity can be ever greater because
there is no acquired immunity for malaria, especially if the diagnosis is made late or if P. falciparum
shows resistance to antimalarial drugs or malaria chemoprophylaxis [16]. Owing to the increased
susceptibility to infection during gestation, pregnant women are more likely to develop severe disease
than their non-pregnant counterparts and hence are encouraged to take antimalarial IPTp [2].
Although about 37 countries has so far introduced IPTp policy [17], poor implementation
and enforcement of these policies are reflected through low coverage and disparities in utilisation
rates [5,18–21]. According to a review study conducted in 2009, the rate of antimalarial drugs uptake
among pregnant women varied from as low as 2% to more than 60% with significant regional and
socioeconomic disparities in utilisation rates [22]. Apart from the healthcare and financial barriers,
previous studies have reported various individual and community-related barriers to the utilisation of
IPTp-SP, including delayed initiation of antenatal care attendance, poor awareness and knowledge
about MiP and the preventive measures [23], stock-outs of free of cost IPTp-SP [20], and spousal
discord [24]. In the wake of this situation, the American Society of Tropical Medicine and Hygiene
held a global ‘Call to Action’ seminar in 2014 with representatives from several countries in SSA to
discuss opportunities for scaling up the coverage of IPTp [4]. As more and more countries in Asia and
South America are approaching malaria elimination and global donor funding for malaria programs
are becoming increasingly scarce [25], countries in SSA are faced with the challenge of continuing the
fight against malaria and addressing the persisting barrier to adoption of preventive measures in the
population. Achieving the target of universal coverage for IPTp is undoubtedly a huge task, one that
needs to be leveraged by more innovative and pro-poor strategies by reducing the accessibility and
affordability barriers to utilisation for which evidence from population-based studies is absolutely
crucial. In this regard, we undertook the present study based on secondary data from Malaria Indicator
Surveys (MIS) conducted in selected malaria-endemic countries in SSA. The main objectives were
to provide updated information regarding the prevalence of IPTp utilization and to investigate the
influence of any socioeconomic factors in the utilization status.
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2. Methods
2.1. Countries Included in the Study
Data were obtained from the Malaria Indicator Surveys (MIS) conducted in eight sub-Saharan
African countries as shown in Figure 1: Burkina Faso (2014), Ghana (2016), Mali (2015), Malawi (2014),
Kenya (2015), Nigeria (2015), Sierra Leone (2016), and Uganda (2014–2015). Surveys were conducted
by technical assistance as well as funding by ICF International through the Demographic and Health
Survey (DHS) Program, which is a USAID-funded project providing support and technical assistance
in the implementation of population and health surveys in countries worldwide [21].
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The respective institutions implementing the surveys are as follows. Burkina Faso: Institut
National de la Statistique et de la Démographie (INSD); Gha a: Ghana Statistical Service (GSS), Kenya:
National Malaria Control Programme (NMCP) of the Ministry of Health and the Kenya National
Bureau of Statistics (KNBS); Malawi: National Mal ria Control Programme (NMCP) of the Ministry of
Health; Mali: INFO-STAT en collaboration av c le Programm National de Lutte contre le Paludisme
(PNLP), Ministère de la Santé et de l’Hygiène Publiqu , et l’Institut National de l Statistique (INSTAT),
Ministère de l’Aménagement du Territoire et de la Population; Sierra Leone: National Malaria Control
Programme (NMCP), Stati tics Sierra Leone (SSL), the College f M dicine and Allied Health S rvic s
(COMAHS) of the Univ rsity of Sierra Le e (USL), and Catholic R lief Services (CRS); Nigeria:
National Malaria Elimination Programme (NMEP), the National Population Commission (NPopC),
and the Natio al Bureau of Statistics (NBS); and Uganda: Uganda Bureau of Statistics (UBOS) and the
National Malaria Control Programme (NMCP) of the Uganda Ministry of Health.
2.2. Survey Design and Objectives
MIS surveys employ stratified two-stage cluster design. In the first stage, sampling strata were
created, from which clusters are selected per stratum by a probability-proportional-to-size selection.
A complete listing in the selected clusters serves as the sampling frame for the second stage. In the
second stage, households are selected from each cluster by equal probability systematic sampling.
Study participants were women aged 15–49 years residing in non-institutional places in urban and
rural areas.
The objectives of the surveys are to provide quality data for measuring progress toward selected
targets and goals required for effective monitoring, and assessing the national malaria program’s
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implementation and measurement. Specifically, the surveys aim to measure the indicators of ownership and
use of mosquito bed nets; coverage of the intermittent preventive treatment programme for pregnant
women; treatment-seeking behaviour; measure indicators of knowledge, attitudes, and behaviour
related to malaria control; and to determine the factors associated with malaria and anaemia. Besides
these questions, many other questions about basic demographics, education, use of ITNs, malaria
prevention practices during pregnancy, and knowledge of malaria are surveyed. Further details on
survey are available from the data sources [26].
2.3. Variables
Outcome variable: The main outcome variable was adequate use of intermittent preventive
therapy with sulfadoxine-pyrimethamine (IPTp-SP). It was assessed by asking the respondents whether
or not they took Fansidar (sulfadoxine-pyrimethamine, SP) during their last pregnancy, and how many
times it was taken. Administration of IPTp-SP during antenatal visits is considered to be one of the
three key interventions recommended by the World Health Organization (WHO) for controlling MiP in
stable malaria transmission areas [4]. Prophylactic administration of SP has been found to be effective
in preventing the consequences of MiP (e.g., low birthweight) [27]. As WHO recommends at least three
doses of SP, for the present study we used the recommendation of three doses to define the adequacy
of IPTp-SP dosage: adequate (>2 doses) and inadequate (≤2 doses).
Independent variables were age: 15–19/20–24/25–29/30–34/35–39/40–44/45–49; setting: urban/rural;
education: no education/primary/secondary/higher; religion: Islam/Christian/Other; wealth index:
poorest/poorer/middle/richer/richest; received malaria information on TV: no/yes; received malaria
information on radio: no/yes; received malaria information from health workers: no/yes.
All the variables were self-reported, except for the wealth index. For the calculation of household
wealth status, instead of direct income, the volume of durable goods (e.g., TV, radio, and bicycle)
possessed by the household as well as and housing quality (e.g., type of floor, wall, and roof) are
taken into consideration. Each item is assigned a factor score generated through principal component
analysis (PCA), which is then summed and standardized for the households. These standardized
scores place the households in a continuous scale based on relative wealth scores. The scores are thus
obtained from a continuous scale and subsequently categorized into quintiles to rank the household as
poorest/poorer/middle/richer/richest to richest [28]. For the present study, households in lowest
two categories were merged and categorized as poor, and those from middle to richest were merged
as non-poor.
2.4. Data Analysis
Statistical analyses were performed with SPSS version 24. Firstly, the datasets were cleaned for
outliers, checked for potential multicollinearity, and then merged to perform pooled analysis. Due to
nonproportional allocation of the samples across the survey regions, they were not self-weighting.
Furthermore, MIS surveys use cluster sampling design. To adjust for sample weight and cluster
sampling techniques, the analysis was preceded by the preparation of complex survey file by
accounting for primary sampling units, sample strata, and sample weight. Prevalence rates of adequate
uptake of IPTp-SP for each explanatory variable were shown as percentages. Country-wise prevalence
of adequate uptake was presented as bubble charts with 95% CIs. After that, binary logistic regression
model was used to calculate the odds ratios of the associations between adequate of IPTp-SP and
women’s educational level and household wealth status while adjusting for potential confounding
variables. Results of regression analysis were presented as odds ratios along with their 95% CIs as an
indicator of significance, as well as of the precision of the OR values. For all associations, p-value of
<0.05 was considered statistically significant.
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2.5. Ethical Approval
The study was based on analysis of anonymized secondary data available in the public domain of
DHS; therefore, no additional approval was necessary. However, approval for the reuse of the data
was obtained by authors from DHS.
3. Results
3.1. Descriptive Statistics
Basic demographic and socioeconomic information of the sample population was summarized in
Table 1. In total, 18,603 women aged between 15–49 years were included in the present study. Mean
age of the participants was 28.76 years (SD 7.01). The overall prevalence of taking adequate doses of
IPTp-SP during the latest pregnancy was 29.5% (95% CI = 28.2–30.5). As clarified in the table, this
prevalence was higher among women aged between 25–29 years who lived in rural settings, had no
education, lived in non-poor households, and received malaria-related information from television,
radio, and health workers.
Table 1. Distribution of sample population across the explanatory variables, MIS 2014–2016.
Received at Least 3 Doses of IPTp-SP in Last Pregnancy
p-Value
N = 18,603 % % 95% CI Lower 95% CI Upper
Age Group (Mean = 28.76)
0.061
15–19 1372 7.4 7.0 6.2 7.8
20–24 4184 22.5 22.1 20.8 23.5
25–29 4829 26.0 25.7 24.4 27.2
30–34 3919 21.1 21.3 20.0 22.7
35–39 2697 14.5 14.5 13.5 15.7
40–44 1208 6.5 7.0 6.3 7.8
45–49 394 2.1 2.3 1.9 2.9
Setting
<0.001Urban 5271 28.3 30.6 27.6 33.7
Rural 13,332 71.7 69.4 66.3 72.4
Religion
<0.001
Islam 8964 48.2 43.8 40.9 46.8
Christian 6082 32.7 32.0 29.6 34.5
Other 3557 19.1 24.2 21.3 27.3
Education
<0.001
No education 8960 48.2 44.3 41.9 46.8
Primary 3895 20.9 22.4 20.9 24.1
Secondary 3676 19.8 25.4 23.5 27.4
Higher 2072 11.1 7.8 6.5 9.4
Wealth index
<0.001
Poorest 4071 21.9 19.0 17.4 20.8
Poorer 3910 21.0 21.1 19.4 23.0
Middle 3850 20.7 20.7 19.1 22.3
Richer 3683 19.8 21.2 19.3 23.1
Richest 3089 16.6 18.1 15.9 20.4
TV *
0.05No 15,013 80.7 22.4 20.3 24.7
Yes 3590 19.3 77.6 75.3 79.7
Radio *
<0.001No 10,008 53.8 45.6 43.3 48.0
Yes 8595 46.2 54.4 52.0 56.7
Health worker *
<0.001No 11,515 61.90 34.7 32.1 37.4
Yes 7088 38.11 65.3 62.6 67.9
MIS = Malaria Indicator Survey; CI = confidence interval; p-values calculated from Chi-square tests of independence;
* = refers to receiving malaria-related information from these sources.
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Figure 2 shows the percentage of women who received three doses of SP during last pregnancy in
the individual countries. Among the eight countries, only Ghana had a prevalence of three doses of
SP taken for more than half of the women (60%), while in Malawi, Nigeria, and Uganda, more than
four-fifth of the women did not get the adequate dosage of SP.Trop. Med. Infect. Dis. 2018, 3, x FOR PEER REVIEW  6 of 11 
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3.2. Regression Analysis on the Association between Educational Level and Wealth Status with the Uptake
of IPTp-SP
Results of regression analysis was summarized in Table 2. As the results indicate, we found a
negative association between the uptake of IPTp-SP with educational status, and positive association
with wealth status. Compared with women who had no formal education, the odds of inadequate
uptake (<3 doses) of IPTp-SP were higher among those with primary (OR = 1.307, 95% CI = 1.104–1.547),
secondary (OR = 1.431, 95% CI = 1.202–1.705), and higher (OR = 1.658, 95% CI = 1.401–1.962)
educational status. With regard to wealth status, women living in the poorest, poorer, middle,
and richer households had respectively 32% (OR = 1.320, 95% CI = 1.140–1.529), 24% (OR = 1.235,
95% CI = 1.069–1.425), 21% (OR = 1.210, 95% CI = 1.054–1.388), 21.2% (OR = 1.212, 95% CI = 1.069–1.374)
higher odds of not taking at least three doses of IPTp-SP during their last pregnancy.
For sensitivity analysis, we ran the regression models by taking two doses of SP as an outcome
variable that generated similar results of inverse relationship between the uptake of IPTp-SP with
educational status, and positive association with wealth status (results not shown). Model fitness
was evaluated by Nagelkerke R squared statistics, which showed satisfactory model fit, as the fully
adjusted model explained 48% of the variance in the outcome variable.
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Table 2. Association between educational level and wealth status with inadequate uptake of IPTp-SP
in pregnancy in selected countries in sub-Saharan Africa, MIS 2014–2016.
Model 1 Model 2 Model 3
OR 95% CILower
95% CI
Upper OR
95% CI
Lower
95% CI
Upper OR
95% CI
Lower
95% CI
Upper
Education (Nil)
Primary 1.791 1.590 2.018 1.307 1.104 1.547
Secondary 2.043 1.796 2.324 1.431 1.202 1.705
Higher 2.374 2.086 2.701 1.658 1.401 1.962
Wealth index (Richest)
Poorest 1.185 1.069 1.314 1.320 1.140 1.529
Poorer 1.137 1.025 1.262 1.235 1.069 1.425
Middle 1.085 0.977 1.205 1.210 1.054 1.388
Richer 1.127 1.014 1.253 1.212 1.069 1.374
Nagelkerke R Square 0.179 0.134 0.484
OR = odds ratio, CI = confidence interval. p < 0.05. Model 1 = only educational status was entered; Model 2 = only
wealth index was entered; Model 3 = adjusted for respondents age, setting, religion, receiving malaria information
from TV, radio, and health worker.
4. Discussion and Policy Recommendation
Our findings revealed that the overall prevalence of adequate uptake of IPTp-SP was remarkably
low, as less than a quarter of the women reported taking at least three doses of SP during their last
pregnancy. This is far below Roll Back Malaria’s (RBM) target of 80% coverage of≥2 doses of IPTp-SP20.
Poor coverage and utilisation of IPTp-SP is a serious concern for malaria prevention and eradication
programs for health NGOs and national governments in SSA [19,29]. There is mounting evidence
regarding the failure of the healthcare systems to promote maternal healthcare services utilisation due
to persisting infrastructural, sociocultural, and financial barriers [30,31]. Thus, it makes sense that even
if IPTp is distributed free or at minimal cost, a great proportion of the women may remain deprived of
antimalarial services due to poor exposure to antenatal contacts. Although we were not able to assess
the influence of antenatal care, in light of the past evidence it is arguable that improving antenatal
care attendances by addressing the contextual barriers might eventually prove beneficial for malaria
prevention programs by increasing the exposure to preventive measures [32,33].
Apart from the low average, there were considerable inter- and intra-country variations in the
adequate uptake of IPTp as well. There are certain difficulties in comparing these findings with
previous ones due to methodological differences. Nonetheless, inadequate use of SP was reported in
Cameroon [34], Gabon [35], Burkina Faso [36], and Benin [37]. A meta-analysis study conducted in
2013 on African countries reported very low prevalence of IPTp uptake; only a quarter of the women
received only one dose [17]. Coverage of IPTp appears to be comparatively better in Ghana and Kenya,
who were among the earliest countries to approve IPTp policy. The prevalence of taking one dose of
IPTp in these two countries was reported to be 80.7% and 35.5%, respectively [29]. In comparison,
the corresponding rates were below 10% in Somalia, Benin, and Congo, while, respectively, they were
12% and 11.8% in Madagascar and Central African Republic [38].
For effectively addressing the poor coverage and utilisation rates, it is absolutely essential to
identify the limiting factors in order to developing evidence-based intervention strategies. In this study,
our choice of predicting the factors was limited, as the data were secondary. However, we assessed the
predictability of individual educational level and household wealth status for the uptake of IPTp-SP.
The role of individual’s socioeconomic status on self-efficacy, awareness, and preventive behaviour is
well-documented. Surprisingly, our findings indicated an inverse relationship between educational
level of adequate uptake of IPTp-SP. In contrast, a cross-sectional study among rural women in Kenya
reported that women who had formal education had higher likelihood of receiving at least one dosage
of IPTp-SP [39]. Similarly, positive association between educational status and IPTp-SP uptake was
observed in Malawi and Uganda [31,40]. While this seems counterintuitive from the perspective
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of health service utilisation, it is hard to explain this irregularity in light of the currently analysis,
and hence remains a subject for investigation by future studies. A possible reason could be that women
with higher educational status are better off financially and can afford healthier living environments,
which makes the use of antimalarial apparently less essential.
As expected, our findings indicate that women living in households relatively poorer than richest
ones were less likely to report taking 2+ doses of IPTp-SP. This enabling effect of financial well-being
on IPTp-SP uptake is in line with previous findings from Kampala, Uganda, and Kibaha District
of Tanzania [41,42]. The financial barrier in this regard may appear irrelevant, as these services are
usually provided free of charge by public establishments. However, although the actual costs of taking
IPTp-SP seem to insignificant, there might be other hidden or perceived costs associated with it, such
as transportation costs or charges for antenatal care. Moreover, even if the products come free of
cost, the expenses related to administration, logistics, and staff management can create the need for
systematic revenue generation that might discourage poor consumers [43]. This can be especially
burdensome for women living in extreme poverty and those who rely on husbands or other household
members to cover such fees. Therefore, it is suggested that health policy makers focus on finding
innovative ways to incentivize service uptake among the ultra-poor, who are usually most at risk of
malaria infection.
From the discussions above, it becomes clear that healthcare systems in sub-Saharan Africa
targeting malaria prevention and elimination are faced with enormous challenges to achieve optimum
coverage and utilization of IPTp-SP. Apart from health infrastructure-related barriers, health policy
makers also need to target the sociocultural, economic, and geographic barriers to maximize the
outcomes of the ongoing efforts. As malaria disproportionately affects women and children, this adds
to their higher vulnerability to poorer socioeconomic status and translates to low health literacy and
treatment-seeking behavior [44]. Therefore, special policy attention is required to safeguard women and
children by making gender- and child-sensitive health policies an integral part of malaria prevention
programs. It is also necessary to bear in mind that encouraging the uptake of antimalarial drugs needs
proper regulation to avoid their incorrect use, especially ones that are no longer recommended and
can undermine malaria control efforts by fuelling drug resistance [45]. Another significant barrier
to making measurable steps towards malaria elimination is the scarcity of quality data. As Richard
Cibulskis (co-ordinator of the global malaria programme of WHO) reported, over 90% of the world’s
malaria cases are likely to go unreported, and the data systems are weakest in the places where malaria
is the most common, and for some African nations there are no good data at all [46]. To ensure
long-term and targeted intervention, national governments in sub-Saharan Africa also need to place
stress on improving health informatics systems for malaria, developing better data collection and
distribution tools, and correctly managing health records.
Strengths and Limitations
Apart from the contribution to the current literature, this study has some important strengths and
limitations that need to be mentioned. The sample size was large and the findings are generalizable
for women aged 15–49 years in the studies countries. Among the limitations were the secondary
nature of the sample that prevented us from having any control over the measurement and selection
of the variables. We were also unable to assess the specific causes behind not using IPTp-SP in the
sample population, except for educational and financial status, which are two well-known enabling
factors of positive health behavior among both men and women. Neither was it possible for us to
identify the causes behind the inverse association between educational status and uptake of IPTp-SP.
The prevalence is also subject to recall error, as women had to remember the use of the service
during their most recent pregnancy, within the last five years. Last but not least, as the data were
cross-sectional, the association cannot guarantee any causation or directionality.
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5. Conclusions
In conclusion, the prevalence of IPTp-SP was alarmingly low with noticeable intra- and
inter-county variations. Despite several important limitations, the findings of the study provide
a fresh insight into the current status of IPTp-SP use during pregnancy in the malaria-endemic
regions in sub-Saharan Africa. The shockingly low prevalence of IPTp-SP utilization implies the
need to strengthen the policy approaches and programmatic actions to address the structural and
socioeconomic factors responsible for the substandard performance of the IPTp policies. Further
studies are recommended to identify the perceived barriers to taking IPTp-SP among pregnant women
in these countries.
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